Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Butterfly Network, Inc.BFLY · Entity 4467 | Director · President and CEO | March 07, 2024 | May 24, 2024 |
| Century Therapeutics, Inc.IPSC · Entity 5739 | Director · President and CEO | September 11, 2026 | September 15, 2026 |
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Butterfly Network, Inc.
Report date March 07, 2024 · Filed May 24, 2024 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2024-03-07 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 0 F1: This Form 4 Amendment is being filed to correct the original Form 4. The original Form 4 was filed erroneously with an incorrect Issuer. The Reporting Person has no affiliation nor does he own any shares of Butterfly Network, Inc. The Reporting Person is the President and CEO of Century Therapeutics, Inc. and a correct Form 4 has been filed. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
Holding disclosure · report date 2024-03-07 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 0 F1: This Form 4 Amendment is being filed to correct the original Form 4. The original Form 4 was filed erroneously with an incorrect Issuer. The Reporting Person has no affiliation nor does he own any shares of Butterfly Network, Inc. The Reporting Person is the President and CEO of Century Therapeutics, Inc. and a correct Form 4 has been filed. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 Amendment is being filed to correct the original Form 4. The original Form 4 was filed erroneously with an incorrect Issuer. The Reporting Person has no affiliation nor does he own any shares of Butterfly Network, Inc. The Reporting Person is the President and CEO of Century Therapeutics, Inc. and a correct Form 4 has been filed.
Century Therapeutics, Inc.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,633,839 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Tax withholding · Disposed 13,850 · Balance 3,633,839 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
Corbus Pharmaceuticals Holdings, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
After 2026-05-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 7,500 · Balance 7,500 F1: On May 19, 2026, 7,500 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date. F2: This amount includes 7,500 unvested RSUs that were granted on May 19, 2026 and will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.15 · Expires 2036-05-19 | Direct | 24,700 |
Reported balance
After 2026-05-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-19 · Grant · Acquired 24,700 · Balance 24,700 F3: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 19, 2026, 7,500 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.
F2: This amount includes 7,500 unvested RSUs that were granted on May 19, 2026 and will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.
F3: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 22:23 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 13,850 | $1.94 | $26,869.00 |
DisclosureSEC source: 0002001162-26-000018 · form4-09152026_100955.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,633,839 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 20:36 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 463 | $2.11 | $976.93 |
DisclosureSEC source: 0002001162-26-000016 · form4-09092026_080950.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,633,839 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 20:17 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 31,172 | $1.92 | $59,850.24 |
DisclosureSEC source: 0002001162-26-000014 · form4-08182026_080855.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,634,302 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 23:55 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 13,849 | $2.24 | $31,021.76 |
DisclosureSEC source: 0002001162-26-000012 · form4-06152026_110631.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,665,474 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:10 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 463 | $2.13 | $986.19 |
DisclosureSEC source: 0002001162-26-000010 · form4-06092026_040603.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,679,323 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:04 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock options (right to buy) · Derivative | 24,700 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001193125-26-234813 · ownership.xml · derivative · entry 2 Pfeiffenberger Brent · CIK 0002001162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,700 Underlying: Common Stock · 24,700 shares Expires 2036-05-19 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:04 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock, par value $0.0001 per share | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-234813 · ownership.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 F1 · shares: On May 19, 2026, 7,500 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date. F2 · balance_after: This amount includes 7,500 unvested RSUs that were granted on May 19, 2026 and will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:10 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 31,172 | $2.34 | $72,942.48 |
DisclosureSEC source: 0002001162-26-000008 · form4-05192026_040501.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,679,786 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:07 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 55,397 | $2.73 | $151,233.81 |
DisclosureSEC source: 0002001162-26-000006 · form4-03132026_080321.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,710,958 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 23:53 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 463 | $2.56 | $1,185.28 |
DisclosureSEC source: 0002001162-26-000004 · form4-03102026_110303.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,766,355 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:12 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 31,172 | $1.75 | $54,551.00 |
DisclosureSEC source: 0001104659-26-017132 · tm266779-1_4seq1.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,766,818 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:22 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 945,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0002001162-26-000002 · form4-02042026_090254.xml · derivative · entry 2 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 945,000 Underlying: Common Stock · 945,000 shares Expires 2036-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:22 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 475,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002001162-26-000002 · form4-02042026_090254.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,797,990 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:38 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | PurchaseCommon Stock | 52,000 | $0.58 | $30,352.40 |
DisclosureSEC source: 0002001162-25-000009 · form4-12162025_111214.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,322,990 F1 · kind: All profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.577 to $0.5838. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:16 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 463 | $0.53 | $243.54 |
DisclosureSEC source: 0002001162-25-000007 · form4-12122025_091213.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,270,990 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 23:02 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | PurchaseCommon Stock | 35,000 | $0.50 | $17,328.50 |
DisclosureSEC source: 0002001162-25-000005 · form4-11202025_111138.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,271,453 F1 · kind: All profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.488 to $0.5005. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:19 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 32,456 | $0.45 | $14,735.02 |
DisclosureSEC source: 0002001162-25-000003 · form4-11192025_091118.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,236,453 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 21:29 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 488 | $0.50 | $244.00 |
DisclosureSEC source: 0001062993-25-015525 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,268,909 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:14 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 1,587,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014562 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,269,397 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 50% on August 14, 2027, with the remaining 50% vesting on August 14, 2028, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 21:05 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 475 | $0.62 | $295.45 |
DisclosureSEC source: 0001062993-25-011427 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,681,783 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:19 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 29,552 | $0.55 | $16,135.39 |
DisclosureSEC source: 0001062993-25-009868 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,682,258 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:30 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 521,500 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001062993-25-005292 · form4.xml · derivative · entry 3 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,500 Underlying: Common Stock · 521,500 shares Expires 2035-03-11 F3 · derivative.exercise_date: The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:30 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 521,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-005292 · form4.xml · nonDerivative · entry 2 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,711,810 F2 · kind: Reflects the grant of RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:30 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 2,235 | $0.62 | $1,374.53 |
DisclosureSEC source: 0001062993-25-005292 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,190,310 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:00 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 34,712 | $0.78 | $27,179.50 |
DisclosureSEC source: 0001062993-25-003043 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,192,545 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:57 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Tax withholdingCommon Stock | 243,447 | $1.44 | $350,563.68 |
DisclosureSEC source: 0001062993-24-020202 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,227,257 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 23:37 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | GrantStock Option (right to buy) · Derivative | 104,550 | $0.00 Strike: $5.32 | $0.00 |
DisclosureSEC source: 0001062993-24-006184 · form4.xml · derivative · entry 2 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,550 Underlying: Common Stock · 104,550 shares Expires 2034-03-07 F2 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 23:37 UTC | Butterfly Network, Inc. BFLY · Entity 4467 | GrantCommon Stock | 17,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-006184 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,470,704 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| March 07, 2024 Filed Mar 18, 2024 21:48 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 104,550 | $0.00 Strike: $5.32 | $0.00 |
DisclosureSEC source: 0001062993-24-006667 · form4.xml · derivative · entry 2 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,550 Underlying: Common Stock · 104,550 shares Expires 2034-03-07 F2 · date: This Form 4 was originally filed under the incorrect Issuer on March 11, 2024 due to an administrative error (the "Original Form 4"). The Original Form 4 is being refiled to appear associated with the correct Issuer. F3 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| March 07, 2024 Filed Mar 18, 2024 21:48 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 17,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-006667 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,470,704 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. F2 · date: This Form 4 was originally filed under the incorrect Issuer on March 11, 2024 due to an administrative error (the "Original Form 4"). The Original Form 4 is being refiled to appear associated with the correct Issuer. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:07 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 573,691 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022023 · form4.xml · derivative · entry 3 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 573,691 Underlying: Common Stock · 573,691 shares Expires 2033-12-04 F3 · derivative.exercise_date: The option vests 25% on December 4, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:07 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 279,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022023 · form4.xml · nonDerivative · entry 2 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,453,279 F2 · security: Reflects a grant of RSUs. The RSUs underlying this grant shall vest in full on December 4, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:07 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 1,173,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022023 · form4.xml · nonDerivative · entry 1 Pfeiffenberger Brent · CIK 0002001162 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,173,775 F1 · security: Reflects a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs underlying this grant shall vest 25% on December 4, 2024, with the remaining 75% vesting in one-twelfth (1/12th) increments on each of the first trading days on or after each of February 15, May 15, August 15, and November 15, subject to the Reporting Person's continued service through each applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.